Step 1 topics → Endocrine → Thyroid Cancers (Papillary, Follicular, Medullary, Anaplastic)

Thyroid Cancers (Papillary, Follicular, Medullary, Anaplastic)

USMLE Step 1 trap: Misattributes papillary thyroid carcinoma's spread to hematogenous rather than lymphatic routes. Papillary thyroid carcinoma spreads primarily via lymphatics to regional cervical lymph nodes, not hematogenously.

Thyroid cancer shows up on USMLE Step 1 as four distinct diseases that happen to share an organ. The exam expects you to keep them separate — each has a unique cell of origin, histologic finding, spread pattern, and clinical association. Papillary is the most common and the most tested. Medullary is the highest-yield for associations (MEN2, calcitonin). Follicular and anaplastic round out the picture but have their own specific traps. If you blur these together, you'll miss questions that hinge on one distinguishing detail.

The testing angles range from pure recall (what are psammoma bodies?) to application (a patient has a thyroid mass and elevated calcitonin — what syndrome do you screen for?) to passage interpretation (a cytology report says 'follicular neoplasm' — what's the next step and why?). USMLE Step 1 loves to embed these in vignettes where the diagnosis is implied by histology or lab findings rather than stated directly. You need to read the clue — 'Orphan Annie eye nuclei,' 'amyloid stroma,' 'capsular invasion on surgical specimen' — and immediately know what you're dealing with.

The tricky part is that students conflate the cancers' properties in predictable ways: papillary gets mistakenly assigned hematogenous spread (that's follicular), follicular gets mistakenly diagnosed by FNAB (you can't — you need surgery), and medullary gets the wrong tumor marker (calcitonin, not thyroglobulin). The workup sequence also trips people up because jumping straight to biopsy skips the TSH step that actually drives the decision tree. Nail the distinguishing features of each type and understand the logic of the workup, and this becomes a reliable point-getter on exam day.

From real student decks
89%have cards covering this topic
78%have mature cards
2median lapses in 14 days

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Papillary thyroid carcinoma spreads primarily via hematogenous routes.
Right: Papillary thyroid carcinoma spreads primarily via lymphatics to regional cervical lymph nodes, not hematogenously.
Papillary thyroid carcinoma spreads via the lymphatic system, not the bloodstream — this is the opposite of what many students assume because hematogenous spread feels like 'classic cancer behavior.' The lymphatic route explains why you find regional cervical lymph node metastases early in the disease; paradoxically, even with nodal spread, prognosis remains excellent. Hematogenous spread to lung and bone is the signature of follicular carcinoma, so if you see 'bone or lung metastasis' in a thyroid cancer vignette, think follicular, not papillary.
Common mistake
Wrong: Fine-needle aspiration biopsy (FNAB) can definitively diagnose follicular thyroid carcinoma.
Right: Follicular thyroid carcinoma requires surgical excision for diagnosis because malignancy is defined by capsular or vascular invasion, which cannot be assessed on FNAB cytology.
FNAB samples cells, not tissue architecture — and follicular carcinoma is defined entirely by architecture: specifically, whether tumor cells invade through the capsule or into blood vessels. A follicular neoplasm on cytology looks identical whether it's benign (follicular adenoma) or malignant; the only way to tell them apart is to examine the capsule under the microscope after surgical excision. This is why 'follicular neoplasm' on FNAB mandates surgical resection, not a repeat biopsy or watchful waiting.
Common mistake
Wrong: Medullary thyroid carcinoma is monitored with thyroglobulin levels.
Right: Medullary thyroid carcinoma is monitored with calcitonin (and CEA), not thyroglobulin, because it arises from parafollicular C cells.
Thyroglobulin is produced by follicular cells and is the tumor marker for differentiated thyroid cancers (papillary and follicular) after thyroidectomy. Medullary carcinoma arises from parafollicular C cells, which have nothing to do with thyroglobulin — they make calcitonin. Using calcitonin (and CEA) as the marker makes mechanistic sense once you remember the cell of origin. On Step 1, if a vignette mentions calcitonin, immediately think medullary thyroid carcinoma and consider screening for RET mutation and MEN2.
Common mistake
Wrong: The first step in evaluating a thyroid nodule is ultrasound-guided FNAB.
Right: The first step in thyroid nodule workup is TSH measurement; a low TSH prompts RAIU scan to identify a hot nodule (rarely malignant), while a normal or high TSH leads to ultrasound and FNAB.
Jumping straight to FNAB wastes the information TSH provides before you even touch the nodule. A suppressed TSH means the nodule is likely hyperfunctioning ('hot'), and hot nodules almost never turn out to be malignant — RAIU scan confirms this and may spare the patient an unnecessary biopsy. A normal or elevated TSH means the nodule is not autonomously functioning, raising the malignancy risk enough to warrant ultrasound characterization and FNAB. The sequence TSH → RAIU (if low TSH) or ultrasound/FNAB (if normal/high TSH) is the clinical logic USMLE Step 1 expects you to apply.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Papillary thyroid carcinoma: know the classic histologic findings (Orphan Annie eye nuclei, nuclear grooves, psammoma bodies), that it spreads via lymphatics to cervical nodes (not hematogenously), and that radiation exposure is the key modifiable risk factor.
  2. Follicular thyroid carcinoma: know that FNAB cannot diagnose it — malignancy requires demonstration of capsular or vascular invasion on surgical histology — and that unlike papillary, it spreads hematogenously to lung and bone.
  3. Medullary thyroid carcinoma: know it arises from parafollicular C cells (not follicular cells), secretes calcitonin (the tumor marker used for diagnosis and surveillance), and is associated with MEN2A and MEN2B.
  4. Anaplastic thyroid carcinoma: know it occurs in elderly patients, presents as a rapidly enlarging fixed neck mass causing compressive symptoms, and carries an extremely poor prognosis (median survival weeks to months).
  5. Thyroid nodule workup: know that TSH is always the first step — a suppressed TSH triggers a radioactive iodine uptake scan to identify a hot nodule (rarely malignant), while a normal or elevated TSH leads to ultrasound and then FNAB.

Can you avoid these mistakes?

A 35-year-old woman with a history of childhood neck irradiation has a 1.5 cm thyroid nodule. TSH is normal. Ultrasound shows a solid hypoechoic nodule with microcalcifications. FNAB shows cells with ground-glass nuclei and intranuclear inclusions. What is the diagnosis, and where is this cancer most likely to spread first?
A surgeon resects a thyroid nodule that was read as 'follicular neoplasm' on preoperative FNAB. The pathologist's report states 'follicular cells with capsular invasion identified.' Why couldn't FNAB make this diagnosis, and what determines whether this lesion is adenoma versus carcinoma?
A 45-year-old man is found to have a thyroid nodule and a serum calcitonin of 850 pg/mL (markedly elevated). What is the cell of origin of his likely cancer, what additional genetic test should be ordered, and why is thyroglobulin NOT the appropriate surveillance marker here?
A 72-year-old woman presents with a rapidly enlarging neck mass, hoarseness, and dysphagia over 6 weeks. The mass is rock-hard and fixed on exam. What thyroid cancer is most likely, and what is the expected prognosis? Separately, if her initial TSH had come back suppressed rather than elevated, how would the workup algorithm have differed?

Related topics

Hypothalamic-Pituitary-Thyroid (HPT) Axis Hypothalamic-Pituitary-Adrenal (HPA) Axis Hypothalamic-Pituitary-Gonadal (HPG) Axis Hormone Signaling (Peptide vs Steroid)

See how your Anki deck covers this topic.

Upload your deck for a free audit →